 is seeking to participate in the Drug Enforcement Administration’s upcoming){kind=link}
The National Organization for the Reform of Marijuana Laws (NORML) is seeking to participate in the Drug Enforcement Administration’s upcoming administrative hearing regarding the broad rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA).
The hearing, set for June 29, will consider the 2023 recommendation by the Department of Health and Human Services to reclassify cannabis broadly under the CSA and is separate from the recent decision by the federal government to move medical cannabis from Schedule I to Schedule III.
NORML wants to be a formal “interested party” in the hearing. They argue that without adult cannabis users’ perspectives, the records will not be complete.
In a statement, Joseph A. Bondy, chair of NORML’s board of directors and counsel to NORML, said that “Adult cannabis consumers do not become patients because federal law lacks a better category for them.”
Marijuana is not allowed to remain on Schedule I. The road isn’t over with Schedule III. This is at best an interim fix. The federal government continues to fail to acknowledge adult cannabis users who act lawfully according state laws.” — Bondy in a statement
NORML’s filing contends that federal scheduling of cannabis directly affects consumers’ legal status, their access to tested and labeled products, exposure to collateral consequences, and their ability to participate safely state-regulated markets. The filing further argues that a Schedule III rule, if treated as final, would continue to leave adult-use cannabis consumers federally exposed while medicalizing lawful cannabis use.
NORML previously filed to participate in hearings scheduled for last year – which were ultimately canceled – but was not among the parties selected.
Cannabis Law Resources for Poland
Browse essential legal pages on cannabis sales and cultivation in Poland. These guides will help you understand the legal requirements, such as certifications and permissions.
-
Polish News Registration and Interests of Cannabis Businesses
-
Permissions for Cannabis Sales in Poland
-
Authorization for Importing or Manufacturing Medical Products
-
Permission for Manufacturing or Importing Medical Products
-
Certificate of Good Manufacturing Practices (GMP)
-
Registration of Medical Products in Poland